Exthymic lands $25M ARPA-H grant for cell therapy device
What's the deal? San Diego-based Exthymic Corporation has been awarded up to $25 million by the Advanced Research Projects Agency for Health (ARPA-H), an agency within the US Department of Health and Human ServicesDealroom has a profile for this one. Try Dealroom →. The contract funds development of a cell therapy device aimed at the issues underlying patient access and affordability.
What's the endgame? Cell therapies can be highly effective but remain expensive and hard to access for many patients. Exthymic is building a device to tackle those cost and access barriers directly.
Why ARPA-H? ARPA-H funds high-risk, high-reward health research the private market often won't touch. Backing a device meant to make cell therapy more affordable fits that mandate.
The signal: At $25 million, this grant ranks among the largest in its category — above roughly 97% of all US health grants on record. That scale underscores how seriously federal funders are treating the affordability gap in advanced therapies.
Read more: vcnewsdaily.com
Image credit: Generated with Gemini
